Trial reportCirculation. Cardiovascular genetics2014
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
Trial report in Circulation. Cardiovascular genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00246519 (Pharmacogenomic Evaluation of Antihypertensive Responses), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.Metabolic syndrome and related disorders · 2015Trial
- Circulating plasma microRNA expression profile: potential minimally invasive biomarker for early detection of coronary artery disease development.Molecular biology reports · 2025Article
- Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes.Journal of internal medicine · 2025Review
- Article
- Antihypertensives associated adverse events: a review of mechanisms and pharmacogenomic biomarkers available evidence in multi-ethnic populations.Frontiers in pharmacology · 2023Review
- Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.Journal of translational medicine · 2021Review
- How Perturbated Metabolites in Diabetes Mellitus Affect the Pathogenesis of Hypertension?Frontiers in physiology · 2021Review
- The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative.Menopause (New York, N.Y.) · 2020Observational
- Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine.Metabolites · 2020Review
- Article
- Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.Journal of the American Heart Association · 2017Article
- Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.International journal of epidemiology · 2016Review
- Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.Metabolomics : Official journal of the Metabolomic Society · 2016Article
- A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.Hypertension (Dallas, Tex. : 1979) · 2016Article
- Hypertension pharmacogenomics: in search of personalized treatment approaches.Nature reviews. Nephrology · 2016Review
- Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes.CPT: pharmacometrics & systems pharmacology · 2015Article
- Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.Clinical pharmacology and therapeutics · 2015Review
- Metabolomics enables precision medicine: "A White Paper, Community Perspective".Metabolomics : Official journal of the Metabolomic SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThe 5-amino acid (AA) signature, including isoleucine, leucine, valine, tyrosine, and phenylalanine, has been associated with incident diabetes mellitus and insulin resistance. We investigated whether this same AA signature, single-nucleotide polymorphisms in genes in their catabolic pathway, was associated with development of impaired fasting glucose (IFG) after atenolol treatment. METHODS AND
resultsAmong 234 European American participants enrolled in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study and treated with atenolol for 9 weeks, we prospectively followed a nested cohort that had both metabolomics profiling and genotype data available for the development of IFG. We assessed the association between baseline circulating levels of isoleucine, leucine, valine, tyrosine, and phenylalanine, as well as single-nucleotide polymorphisms in branched-chain amino-acid transaminase 1 (BCAT1) and phenylalanine hydroxylase (PAH) with development of IFG. All baseline AA levels were strongly associated with IFG development. Each increment in standard deviation of the 5 AAs was associated with the following odds ratio and 95% confidence interval for IFG based on a fully adjusted model: isoleucine 2.29 (1.31-4.01), leucine 1.80 (1.10-2.96), valine 1.77 (1.07-2.92), tyrosine 2.13 (1.20-3.78), and phenylalanine 2.04 (1.16-3.59). The composite P value was 2×10(-5). Those with PAH (rs2245360) AA genotype had the highest incidence of IFG (P for trend=0.0003).
conclusionsOur data provide important insight into the metabolic and genetic mechanisms underlying atenolol-associated adverse metabolic effects. Clinical Trial Registration- http://www.clinicaltrials.gov; Unique Identifier: NCT00246519.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.